North America, the biodefense market, is anticipated to reach US$ 3,357.83 Mn in 2027 from US$ 1,569.29 Mn in 2019. The market is projected to grow with a CAGR of 10.1% from 2019-2027.
The biodefense market is growing primarily due to the presence of favorable government initiatives and increase in the number of naturally occurring outbreaks. Restraining factors, such as Limited Reach of biodefense organizations, are likely to damage the growth of the market in the coming years. On the other hand, increasing adoption of technologies is expected to have a positive impact on the growth of the North American biodefense market in the coming years.
Biodefense is referred to the measures taken to restore biosecurity of a group of organisms that are, or may be, subject to biological threats or infectious diseases. It is an effective public health care system with strong disease surveillance and rapid actions designed to counter biological threats, to limit the spread of disease and provide surge medical care.
Every year, the government is spending heavily on the R&D of vaccines to stay prepared for any bioterrorism attacks. For instance, in 2018, the US government released the National Biodefense Strategy and Implementation Plan, the National Security Strategy, the National Defense Strategy, and the National Counterterrorism Strategy, and the National Counter WMD Strategy, all of which include biosecurity and biodefense. In addition, the US government is also preparing for Global Health Security Strategy and supporting the development of a 2024 framework of the Global Health Security Agenda, which involves prevention, detection, and response to natural, accidental, and intentional biological threats. Enhances Influenza Vaccines and Health Security is the Budget which supports the Executive Order 13887, ?Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health,? by providing a $95 million increase, compared to the 2020 enacted level, across Health and Human Services (HHS) for influenza vaccine manufacturing infrastructure and innovation; advanced research and development of improved vaccines, therapeutics, and diagnostics; international pandemic preparedness; and improved vaccine coverage nationwide. The Budget also funds HHS biodefense and emergency preparedness procurement through the BioShield program and the Strategic National Stockpile. It includes $175 million to support CDC?s global health security activities, an increase of $50 million compared to the 2020 enacted level.
In 2004, the United States Congress passed the Project BioShield Act, calling for USD 5 billion investments for purchasing vaccines, which can be used in the event of a bioterrorist attack. This act was designed to acquire medical countermeasures to biological, chemical, radiological, and nuclear agents, for civilian use. Various initiatives have been planned, particularly in the matured markets, such as North America. For example, in 2017, more than 50 public and private sector biosecurity stakeholders engaged in a meeting in Johns Hopkins Center, Washington DC, for recommendations toward the National Biodefense Strategy and Implementation Plan.
As the government engages in these current and future policy activities, understanding the existing biosecurity and biodefense policy, the pharmaceutical companies operating in the biodefense market have considerable opportunities to expand and be prepared for any bioterrorism. For instance, Antibiotic developer, Spero Therapeutics has received $15.7 million in federal research funding from Biomedical Advanced Research and Development Authority for its oral carbapenem-class candidate, SPR994, to evaluate the drug?s effectiveness against biological threats, including anthrax, plague and melioidosis. In addition, Biomedical Advanced Research and Development Authority also includes provisions for up to an additional $28.5 million over five years, and will also support Spero?s clinical development of SPR994 in complicated urinary tract infections caused by drug-resistant bacteria. The initiatives of governments worldwide open a window of opportunities for the firms involved in the biodefense sector.
In 2019, the Anthrax segment accounted for the largest market share in the North American biodefense market. The similar segment is also estimated to mark the highest CAGR in the market during the forecast period, owing to continue its dominance over the forecast period owing to increasing funding by the governments of other countries to develop and stockpile adequate vaccines against anthrax mainly through a variety of initiatives, such as BioShield Act, Biomedical Advanced Research and Development Authority (BARDA), and the Joint Program Executive Office for Chemical & Biological Defense.
Some of the significant primary and secondary sources for biodefense included in the report are Centers For Disease Control And Prevention (CDC), Food and Drug Administration (FDA), Health and Human Services (HHS), National Health Service (NHS), Nuclear Threat Initiative (NTI) and among others.